SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage IB to III Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effectiveness stereotactic body radiation
therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as
treatment for operable stage IB (tumors > 4cm) to III non-small cell lung cancer (NSCLC)
prior to surgery.